FDA Approves Aloxi for Chemotherapy-Induced Nausea and Vomiting (CINV)
Aloxi (palonosetron) is a 5-HT3 receptor antagonist indicated for the prevention of delayed CINV caused by moderately emetogenic cancer chemotherapy.Posted: July 2003
Related articles
- FDA Approves Aloxi (palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting - August 25, 2008
- FDA Approves Aloxi (palonosetron HCl) Injection for Prevention ofPostoperative Nausea and Vomiting - March 3, 2008
- MGI Pharma and Helsinn Announce Aloxi sNDA Approval Allowing forRepeated Dosing for Cancer Patients Receiving Multiple DayChemotherapy Regimens - September 4, 2007
- MGI Pharma and Helsinn Announce Aloxi sNDA for PONV Accepted for Review By U.S. FDA - July 9, 2007
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
